Intellia Therapeutics (NTLA) PT Lowered to $41 at Leerink Partners

Leerink Partners analyst Mani Foroohar lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $41.00 (from $42.00) while maintaining a Outperform rating.

The analyst comments "Bottom Line: We update our NTLA model for financial disclosures on quarterly earnings, and push nex-z ATTRCM launch from late 2029 to 2030 based on management commentary on the call, marginally decreasing our PT from $42 to $41. We reiterate our OP rating."

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49